MabTics

MabTics is a South Korean biotechnology company specializing in the discovery and development of novel antibody therapeutics, with a primary focus on vessel normalization to treat intractable vascular diseases and cancers. Spun off from the Korea Research Institute of Bioscience and Biotechnology (KRIBB) in 2022, the company leverages its proprietary EAGLES (Exceptional Antibody Generation by Library Engineering and Screening) platform, which utilizes a highly diverse human antibody library and AI-driven optimization. MabTics has established a strategic partnership with Curacle to co-develop a robust pipeline of monoclonal and bispecific antibodies, including candidates targeting Tie2 activation, VEGF inhibition, and the complement C5 axis. Notably, its lead bispecific program MT-103 (MMT-205) was out-licensed to U.S.-based Memento Medicines in 2026 in a global deal valued at up to $1.08 billion.